Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Age: Adult (18–64)

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).

Trial Age: Adult (18–64)

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab in Second-line + Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

August 30, 2023

By Harrison

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors

August 25, 2023

By Harrison

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with histologically or cytologically confirmed

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma

August 2, 2023

By Harrison

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma

June 20, 2023

By Tyler Kalist

This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated

A Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A In Advanced Solid Tumors

June 5, 2023

By clique_admin

This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with MK-5180 when administered as a SC injection to participants with advanced solid tumors. Participants will receive

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Study

May 19, 2023

By clique_admin

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

April 4, 2023

By Tyler Kalist

The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator’s choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR) in

A Study to Evaluate Pembrolizumab in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein / Programmed Cell Death Ligand 1 Treatment

April 4, 2023

By Tyler Kalist

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants

Study of Pembrolizumab Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥50%

March 30, 2023

By Tyler Kalist

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation

A Study of Coformulated Favezelimab/Pembrolizumab Versus Physician’s Choice Chemotherapy in PD-1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

March 30, 2023

By Tyler Kalist

The purpose of this study is to compare efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) with physician’s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma.

Posts navigation

Older posts
logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility